Catalog No.
DHD17203
Host species
Homo sapiens
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
1 mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG2-kappa
Applications
Research Grade Biosimilar
Target
CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P16410
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
Ticilimumab, CP-675, CP-675, 206, CP-675206 clone 11.2.1, CAS: 745013-59-6
Note
For research use only. Not suitable for clinical or therapeutic use.
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial, PMID: 32271377
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial, PMID: 33285097
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study, PMID: 32294530
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial, PMID: 32971005
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer, PMID: 32201234
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial, PMID: 30383184
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma, PMID: 27816492
Tremelimumab, PMID: 20698721
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment, PMID: 32778095
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study, PMID: 26858122
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial, PMID: 31590988
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma, PMID: 31676670
Tremelimumab for the treatment of malignant mesothelioma, PMID: 26560442
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial, PMID: 31318392
Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study, PMID: 31948903
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C, PMID: 23466307
Tremelimumab: research and clinical development, PMID: 27042127
Tremelimumab: a review of development to date in solid tumors, PMID: 23444951
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis, PMID: 30242316
Tremelimumab-Induced Graves Hyperthyroidism, PMID: 28785544
Immunotherapy in Small Cell Lung Cancer, PMID: 32899891
Immune checkpoint inhibitors for hepatocellular carcinoma, PMID: 31290997
Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer, PMID: 30578687
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer, PMID: 17673618
The role of immunotherapy in small cell lung cancer, PMID: 30637710
Management of immune-related adverse events and kinetics of response with ipilimumab, PMID: 22614989
Genetic basis for clinical response to CTLA-4 blockade in melanoma, PMID: 25409260
Antibodies to watch in 2019, PMID: 30516432
Immune checkpoint inhibitor-induced musculoskeletal manifestations, PMID: 32743706
Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: A systematic review and meta-analysis, PMID: 32664183
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis, PMID: 30409774
Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review, PMID: 34105088
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study, PMID: 29773326
Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study, PMID: 32586937
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies, PMID: 29576375
[Classification and etiology of hyperthyroidism], PMID: 24779222
Durvalumab for the treatment of non-small cell lung cancer, PMID: 31782989
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study, PMID: 32379280
Clinical development of the anti-CTLA-4 antibody tremelimumab, PMID: 21074059
Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes, PMID: 29138342
Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy, PMID: 31801732
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies, PMID: 32020438
Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial, PMID: 33279854
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07, PMID: 33026712
Systemic Therapy for Hepatocellular Carcinoma: Latest Advances, PMID: 30380773
Retrospective Chart Review of Cutaneous Adverse Events Associated with Tremelimumab in 17 Patients, PMID: 30073495
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma, PMID: 33046869
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review, PMID: 31374917
Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206), PMID: 19001146
Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives, PMID: 32392774
For research use only. Not for human or drug use.
